Literature DB >> 14668703

Insulin resistance in dilated cardiomyopathy.

Ankur Shah1, Richard P Shannon.   

Abstract

The recognition that insulin resistance is an accompaniment to advanced dilated cardiomyopathy is a relatively recent revelation, but the consequences may be considerable for the failing heart. The failing heart develops a dependence on glucose as its preferred metabolic substrate, given the efficiency of glucose oxidation in the generation of high-energy phosphates. The increased preference for glucose oxidation requires that glucose transport and oxidation be highly regulated. Myocardial insulin resistance in advanced dilated cardiomyopathy limits both glucose uptake and oxidation and impairs the heart's ability to generate much needed adenosine triphosphate. We provide evidence of insulin resistance in dilated cardiomyopathy and explore the relationship to increased sympathetic nervous system activation, lipolysis, and the subsequent alteration in the insulin signaling cascade. Together, these data provide a growing rationale for the development of clinical strategies to overcome insulin resistance in dilated cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14668703

Source DB:  PubMed          Journal:  Rev Cardiovasc Med        ISSN: 1530-6550            Impact factor:   2.930


  11 in total

1.  Multiphasic Regulation of Systemic and Peripheral Organ Metabolic Responses to Cardiac Hypertrophy.

Authors:  Chong Wee Liew; Shanshan Xu; Xuerong Wang; Maximilian McCann; Hyerim Whang Kong; Andrew C Carley; Jingbo Pang; Giamila Fantuzzi; J Michael O'Donnell; E Douglas Lewandowski
Journal:  Circ Heart Fail       Date:  2017-04       Impact factor: 8.790

2.  Sustained βAR Stimulation Mediates Cardiac Insulin Resistance in a PKA-Dependent Manner.

Authors:  Supachoke Mangmool; Tananat Denkaew; Sarawuth Phosri; Darawan Pinthong; Warisara Parichatikanond; Tsukasa Shimauchi; Motohiro Nishida
Journal:  Mol Endocrinol       Date:  2015-12-11

3.  Leukaemia inhibitory factor stimulates glucose transport in isolated cardiomyocytes and induces insulin resistance after chronic exposure.

Authors:  G Florholmen; G H Thoresen; A C Rustan; J Jensen; G Christensen; V Aas
Journal:  Diabetologia       Date:  2006-02-18       Impact factor: 10.122

Review 4.  Diabetic cardiomyopathy.

Authors:  Ankur A Karnik; Anjali V Fields; Richard P Shannon
Journal:  Curr Hypertens Rep       Date:  2007-12       Impact factor: 5.369

5.  Glucose uptake and lipid metabolism are impaired in epicardial adipose tissue from heart failure patients with or without diabetes.

Authors:  Ana Burgeiro; Amelia Fuhrmann; Sam Cherian; Daniel Espinoza; Ivana Jarak; Rui A Carvalho; Marisa Loureiro; Miguel Patrício; Manuel Antunes; Eugénia Carvalho
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-01-26       Impact factor: 4.310

Review 6.  A "PET" area of interest: myocardial metabolism in human systolic heart failure.

Authors:  Ana Kadkhodayan; Andrew R Coggan; Linda R Peterson
Journal:  Heart Fail Rev       Date:  2013-09       Impact factor: 4.214

7.  Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy.

Authors:  Arpita Kalla Vyas; Kai-Chien Yang; Dennis Woo; Anatoly Tzekov; Attila Kovacs; Patrick Y Jay; Paul W Hruz
Journal:  PLoS One       Date:  2011-02-17       Impact factor: 3.240

Review 8.  β-Adrenergic Receptor and Insulin Resistance in the Heart.

Authors:  Supachoke Mangmool; Tananat Denkaew; Warisara Parichatikanond; Hitoshi Kurose
Journal:  Biomol Ther (Seoul)       Date:  2017-01-01       Impact factor: 4.634

9.  Early impairment of contractility reserve in patients with insulin resistance in comparison with healthy subjects.

Authors:  Christian Cadeddu; Silvio Nocco; Davide Piano; Martino Deidda; Efisio Cossu; Marco Giorgio Baroni; Giuseppe Mercuro
Journal:  Cardiovasc Diabetol       Date:  2013-04-16       Impact factor: 9.951

Review 10.  Oxytocin and cardioprotection in diabetes and obesity.

Authors:  Marek Jankowski; Tom L Broderick; Jolanta Gutkowska
Journal:  BMC Endocr Disord       Date:  2016-06-07       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.